Literature DB >> 27297481

Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.

Dange Li1, Yi Hu2, Jim Werngren3, Mikael Mansjö3, Xubin Zheng1, Francis Drobniewski4, Sven Hoffner5, Biao Xu1.   

Abstract

The aim of this study was to investigate the epidemiology of pyrazinamide (PZA) resistance and the associated risk factors as well as to evaluate the pncA gene loci as a marker for PZA resistance in China. A population-based multicenter study of pulmonary tuberculosis (TB) cases was carried out from 2011 to 2013 in four Chinese districts/counties with different geographic and socioeconomic features. Testing for multidrug-resistant tuberculosis (MDR-TB) and susceptibility to PZA was done by the proportion method on Lowenstein-Jensen medium and Bactec MGIT 960, respectively. Mutations in the pncA gene were identified by sequencing. Among 878 culture-positive cases, 147 (16.7%) were resistant to PZA, with a significantly higher proportion among MDR isolates than among the first-line drug-susceptible isolates (30.2% versus 7.7%; P < 0.001). In total, 136 isolates had a nonsynonymous pncA mutation, with a comparable diagnostic performance between Beijing family and non-Beijing family as well as between MDR-TB and first-line drug-susceptible TB. Furthermore, the mutations in isolates with high-level PZA resistance (MIC > 500 mg/liter) were observed mainly in three regions of the pncA gene (codons 51 to 76, codons 130 to 142, and codons 163 to 180). Patients with prior treatment history had a significantly higher risk for PZA monoresistance (odds ratio [OR], 2.86; 95% confidence interval [CI], 1.363 to 6.015) and MDR PZA resistance (OR, 6.47; 95% CI, 3.186 to 13.15), while the additional factors associated with MDR PZA resistance were the patient's age (OR, 1.02; 95% CI, 1.003 to 1.042), lung cavity (OR, 2.64; 95% CI, 1.296 to 5.391). These findings suggest that it is a priority to identify PZA resistance in MDR-TB and that a rapid molecular diagnostic test based on pncA mutations in the Chinese settings where MDR-TB prevalence is high should be developed.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27297481      PMCID: PMC4997820          DOI: 10.1128/AAC.02687-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

Review 1.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  José A Caminero; Giovanni Sotgiu; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Lancet Infect Dis       Date:  2010-09       Impact factor: 25.071

2.  A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide.

Authors:  Anandi Martin; Howard Takiff; Peter Vandamme; Jean Swings; Juan Carlos Palomino; Françoise Portaels
Journal:  J Antimicrob Chemother       Date:  2006-06-02       Impact factor: 5.790

3.  Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii.

Authors:  X Du; W Wang; R Kim; H Yakota; H Nguyen; S H Kim
Journal:  Biochemistry       Date:  2001-11-27       Impact factor: 3.162

4.  pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.

Authors:  S J Cheng; L Thibert; T Sanchez; L Heifets; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  A novel method for the rapid and prospective identification of Beijing Mycobacterium tuberculosis strains by high-resolution melting analysis.

Authors:  M Alonso; Y Navarro; F Barletta; M Martínez Lirola; E Gotuzzo; E Bouza; D García de Viedma
Journal:  Clin Microbiol Infect       Date:  2011-03       Impact factor: 8.067

6.  Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Sami O Simons; Jakko van Ingen; Tridia van der Laan; Arnout Mulder; P N Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2011-11-16       Impact factor: 5.948

7.  Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase.

Authors:  Hua Zhang; Jiao-Yu Deng; Li-Jun Bi; Ya-Feng Zhou; Zhi-Ping Zhang; Cheng-Gang Zhang; Ying Zhang; Xian-En Zhang
Journal:  FEBS J       Date:  2008-01-14       Impact factor: 5.542

8.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.

Authors:  G CANETTI; S FROMAN; J GROSSET; P HAUDUROY; M LANGEROVA; H T MAHLER; G MEISSNER; D A MITCHISON; L SULA
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

9.  Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.

Authors:  Pontus Juréen; Jim Werngren; Juan-Carlos Toro; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

10.  Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.

Authors:  K W Lee; J M Lee; K S Jung
Journal:  J Korean Med Sci       Date:  2001-10       Impact factor: 2.153

View more
  11 in total

1.  Pyrazinamide Resistance and Mutation Patterns Among Multidrug-Resistant Mycobacterium tuberculosis from Henan Province.

Authors:  Jie Shi; Ruyue Su; Danwei Zheng; Yankun Zhu; Xiaoguang Ma; Shaohua Wang; Hui Li; Dingyong Sun
Journal:  Infect Drug Resist       Date:  2020-08-20       Impact factor: 4.003

2.  Comparative Utility of Genetic Determinants of Drug Resistance and Phenotypic Drug Susceptibility Profiling in Predicting Clinical Outcomes in Patients With Multidrug-Resistant Mycobacterium tuberculosis.

Authors:  Yang Che; Tianchi Yang; Lv Lin; Yue Xiao; Feng Jiang; Yanfei Chen; Tong Chen; Jifang Zhou
Journal:  Front Public Health       Date:  2021-04-22

3.  Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh.

Authors:  Arfatur Rahman; Sara Sabrina Ferdous; Shahriar Ahmed; S M Mazidur Rahman; Mohammad Khaja Mafij Uddin; Suporn Pholwat; Jean Gratz; Eric Houpt; Sayera Banu
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China.

Authors:  Zhimin Cao; Yuanbo Lan; Ling Chen; Min Xiang; Zhiyuan Peng; Jianyong Zhang; Hong Zhang
Journal:  Infect Drug Resist       Date:  2019-09-30       Impact factor: 4.003

5.  Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.

Authors:  Hui Xia; Susan van den Hof; Frank Cobelens; Yang Zhou; Bing Zhao; Shengfen Wang; Yanlin Zhao
Journal:  BMC Infect Dis       Date:  2020-01-07       Impact factor: 3.090

6.  Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China.

Authors:  Qiao Liu; Dandan Yang; Beibei Qiu; Leonardo Martinez; Ye Ji; Huan Song; Zhongqi Li; Jianming Wang
Journal:  PLoS Negl Trop Dis       Date:  2021-01-20

7.  Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.

Authors:  Yang Che; Dingyi Bo; Xiang Lin; Tong Chen; Tianfeng He; Yi Lin
Journal:  BMC Infect Dis       Date:  2021-06-25       Impact factor: 3.090

8.  Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates.

Authors:  Nguyen Quang Huy; Contamin Lucie; Tran Thi Thanh Hoa; Nguyen Van Hung; Nguyen Thi Ngoc Lan; Nguyen Thai Son; Nguyen Viet Nhung; Dang Duc Anh; Bañuls Anne-Laure; Nguyen Thi Van Anh
Journal:  Emerg Microbes Infect       Date:  2017-10-11       Impact factor: 7.163

9.  Immunological detection of pyrazine-2-carboxylic acid for the detection of pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Edgar A Florentini; Noelia Angulo; Robert H Gilman; Roberto Alcántara; Elisa Roncal; Ricardo Antiparra; Emily Toscano; Katherine Vallejos; Danni Kirwan; Mirko Zimic; Patricia Sheen
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

10.  Phenotypic and genotypic drug sensitivity of Mycobacterium tuberculosis complex isolated from South Omo Zone, Southern Ethiopia.

Authors:  Biniam Wondale; Girmay Medhin; Gemeda Abebe; Samuel Tolosa; Temesgen Mohammed; Takele Teklu; Rembert Pieper; Gobena Ameni
Journal:  Infect Drug Resist       Date:  2018-09-25       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.